» Articles » PMID: 33741950

Deep Generative Neural Network for Accurate Drug Response Imputation

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Mar 20
PMID 33741950
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Citing Articles

Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.

Luo M, Yang J, Schaffer A, Chen C, Liu Y, Chen Y Cancer Discov. 2024; 15(3):511-529.

PMID: 39601595 PMC: 11875934. DOI: 10.1158/2159-8290.CD-24-0827.


DeepDR: a deep learning library for drug response prediction.

Jiang Z, Li P Bioinformatics. 2024; 40(12).

PMID: 39558584 PMC: 11629690. DOI: 10.1093/bioinformatics/btae688.


Drug Sensitivity Prediction Based on Multi-stage Multi-modal Drug Representation Learning.

Song J, Wei M, Zhao S, Zhai H, Dai Q, Duan X Interdiscip Sci. 2024; .

PMID: 39528873 DOI: 10.1007/s12539-024-00668-1.


The pharmacogenomic and immune landscape of snoRNAs in human cancers.

Wang R, Chen C, Liu Y, Luo M, Yang J, Chen Y Cancer Lett. 2024; 605:217304.

PMID: 39426663 PMC: 11898246. DOI: 10.1016/j.canlet.2024.217304.


Variational Approaches for Drug-Disease-Gene Links in Periodontal Inflammation.

Yadalam P, Natarajan P, Saeed M, Ardila C Int Dent J. 2024; 75(1):185-194.

PMID: 39395900 PMC: 11806325. DOI: 10.1016/j.identj.2024.09.025.


References
1.
Cheng F, Jia P, Wang Q, Zhao Z . Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget. 2014; 5(11):3697-710. PMC: 4116514. DOI: 10.18632/oncotarget.1984. View

2.
Kim P, Jia P, Zhao Z . Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study. Brief Bioinform. 2016; 19(3):450-460. PMC: 5952959. DOI: 10.1093/bib/bbw127. View

3.
Dry J, Pavey S, Pratilas C, Harbron C, Runswick S, Hodgson D . Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010; 70(6):2264-73. PMC: 3166660. DOI: 10.1158/0008-5472.CAN-09-1577. View

4.
Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, Kim S . GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 2012; 103(5):913-20. PMC: 7659189. DOI: 10.1111/j.1349-7006.2012.02231.x. View

5.
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y . Role of tumor microenvironment in tumorigenesis. J Cancer. 2017; 8(5):761-773. PMC: 5381164. DOI: 10.7150/jca.17648. View